Fluoxetine plus lithium for treatment of mental health impairment in Long Covid
Abstract Purposes (1) To summarize the mental conditions that may accompany persistent symptoms following acute infection by SARS-CoV-2, often termed Long Covid; (2) to formulate treatment based upon the brain cells that are dominantly affected. Methods (1) Review the reports relating to the mental...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2023-01-01
|
| Series: | Discover Mental Health |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s44192-022-00027-w |
| _version_ | 1797958806349545472 |
|---|---|
| author | Jeffrey Fessel |
| author_facet | Jeffrey Fessel |
| author_sort | Jeffrey Fessel |
| collection | DOAJ |
| description | Abstract Purposes (1) To summarize the mental conditions that may accompany persistent symptoms following acute infection by SARS-CoV-2, often termed Long Covid; (2) to formulate treatment based upon the brain cells that are dominantly affected. Methods (1) Review the reports relating to the mental symptoms occurring in Long Covid. (2) Review the drugs that address the brain cells affected in Long Covid, and suggest pharmacotherapy for those patients whose response to psychotherapy is suboptimal. Results Long Covid affects ~ 10% of patients infected by SARS-CoV-2, and mental symptoms affect ~ 20% of persons with Long Covid. The brain cell-types that have been demonstrated as dominantly affected in Long Covid are astrocytes, oligodendrocytes, neurons, endothelial cells/pericytes, and microglia. Lithium and fluoxetine each address all of those four cell-types. Low dosage of each is likely to be well-tolerated and to cause neither clinically important adverse events (AE) nor serious adverse events (SAE). Conclusion For those patients whose response to psychotherapy is suboptimal, lithium and fluoxetine should be administered in combination for both depth of benefit and reduction of dosages. |
| first_indexed | 2024-04-11T00:23:59Z |
| format | Article |
| id | doaj.art-69ea9c48aa2243e3bdc118a6dd1ed51d |
| institution | Directory Open Access Journal |
| issn | 2731-4383 |
| language | English |
| last_indexed | 2024-04-11T00:23:59Z |
| publishDate | 2023-01-01 |
| publisher | Springer |
| record_format | Article |
| series | Discover Mental Health |
| spelling | doaj.art-69ea9c48aa2243e3bdc118a6dd1ed51d2023-01-08T12:05:53ZengSpringerDiscover Mental Health2731-43832023-01-013111210.1007/s44192-022-00027-wFluoxetine plus lithium for treatment of mental health impairment in Long CovidJeffrey Fessel0Department of Medicine, University of CaliforniaAbstract Purposes (1) To summarize the mental conditions that may accompany persistent symptoms following acute infection by SARS-CoV-2, often termed Long Covid; (2) to formulate treatment based upon the brain cells that are dominantly affected. Methods (1) Review the reports relating to the mental symptoms occurring in Long Covid. (2) Review the drugs that address the brain cells affected in Long Covid, and suggest pharmacotherapy for those patients whose response to psychotherapy is suboptimal. Results Long Covid affects ~ 10% of patients infected by SARS-CoV-2, and mental symptoms affect ~ 20% of persons with Long Covid. The brain cell-types that have been demonstrated as dominantly affected in Long Covid are astrocytes, oligodendrocytes, neurons, endothelial cells/pericytes, and microglia. Lithium and fluoxetine each address all of those four cell-types. Low dosage of each is likely to be well-tolerated and to cause neither clinically important adverse events (AE) nor serious adverse events (SAE). Conclusion For those patients whose response to psychotherapy is suboptimal, lithium and fluoxetine should be administered in combination for both depth of benefit and reduction of dosages.https://doi.org/10.1007/s44192-022-00027-wSARS-CoV-2Long CovidMental symptomsTreatmentFluoxetine lithium |
| spellingShingle | Jeffrey Fessel Fluoxetine plus lithium for treatment of mental health impairment in Long Covid Discover Mental Health SARS-CoV-2 Long Covid Mental symptoms Treatment Fluoxetine lithium |
| title | Fluoxetine plus lithium for treatment of mental health impairment in Long Covid |
| title_full | Fluoxetine plus lithium for treatment of mental health impairment in Long Covid |
| title_fullStr | Fluoxetine plus lithium for treatment of mental health impairment in Long Covid |
| title_full_unstemmed | Fluoxetine plus lithium for treatment of mental health impairment in Long Covid |
| title_short | Fluoxetine plus lithium for treatment of mental health impairment in Long Covid |
| title_sort | fluoxetine plus lithium for treatment of mental health impairment in long covid |
| topic | SARS-CoV-2 Long Covid Mental symptoms Treatment Fluoxetine lithium |
| url | https://doi.org/10.1007/s44192-022-00027-w |
| work_keys_str_mv | AT jeffreyfessel fluoxetinepluslithiumfortreatmentofmentalhealthimpairmentinlongcovid |